Physician profile
John Waters
NPI 1033176656
$4,181.34
in general payments reported to CMS, 2019-2025
33 companies · $679 in 2025
The $679 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $505 · 2021: $289 · 2022: $177 · 2023: $73.67 · 2024: $994 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $510.74 | 2019-2024 | Repatha |
| Inari Medical, INC. | $444.55 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $399.37 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $322.17 | 2019-2025 | Farxiga, Fasenra, Wainua |
| Boston Scientific Corporation | $255.50 | 2019-2024 | Synergy, Wolverine Coronary Cutting Balloon |
| Regeneron Healthcare Solutions, INC. | $209.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $190.92 | 2019-2025 | |
| Pfizer INC. | $166.06 | 2020-2024 | |
| Chiesi USA, INC. | $152.57 | 2022-2024 | Kengreal, Cleviprex |
| Shockwave Medical, INC | $139.08 | 2025 | |
| Astellas Pharma US INC | $126.40 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.56 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.67 | 2020-2025 | Camzyos |
| Abiomed | $106.60 | 2021-2025 | Impella |
| Stryker Corporation | $99.98 | 2025 | Artix Mt, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $99.45 | 2024 | Zio Monitor, Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.04 | 2019-2022 | |
| Esperion Therapeutics, INC. | $70.87 | 2020-2021 | |
| Abbott Laboratories | $68.65 | 2025 | Xience Skypoint, Diamondback Coronary |
| Lantheus Medical Imaging, INC. | $61.70 | 2019-2024 | |
| Heartflow, INC. | $56.50 | 2025 | |
| Scpharmaceuticals INC. | $47.43 | 2023-2024 | |
| Cardiva Medical, INC. | $43.59 | 2020 | |
| Philips North America LLC | $42.76 | 2022 | |
| Organogenesis INC. | $42.33 | 2025 | Puraply Wound Matrix |
| Actelion Pharmaceuticals US, INC. | $37.13 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $32.79 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $30.15 | 2024-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $23.85 | 2019 | |
| Novo Nordisk INC | $22.67 | 2020 | |
| Teleflex LLC | $20.37 | 2025 | Guideliner |
| Genzyme Corporation | $19.64 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.27 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.